🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 15 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 19/04/1999 | 11,88 | 11,94 | 11,25 | 11,30 | -6,59% | 5,79% | 524.800 |
| 16/04/1999 | 12,13 | 12,56 | 11,91 | 12,09 | +0,78% | 5,41% | 2.174.600 |
| 15/04/1999 | 12,38 | 12,50 | 11,69 | 12,00 | -1,54% | 6,57% | 304.200 |
| 14/04/1999 | 12,56 | 12,56 | 12,13 | 12,19 | +0,26% | 3,48% | 83.800 |
| 13/04/1999 | 13,00 | 13,19 | 12,13 | 12,16 | -6,94% | 8,17% | 198.400 |
| 12/04/1999 | 12,47 | 13,19 | 12,19 | 13,06 | +4,50% | 8,02% | 264.400 |
| 09/04/1999 | 11,69 | 12,50 | 11,69 | 12,50 | +6,67% | 6,95% | 785.800 |
| 08/04/1999 | 12,06 | 12,25 | 11,63 | 11,72 | -3,35% | 5,18% | 465.600 |
| 07/04/1999 | 12,06 | 12,38 | 11,94 | 12,13 | +0,00% | 3,63% | 215.600 |
| 06/04/1999 | 12,56 | 12,56 | 11,88 | 12,13 | -3,24% | 5,47% | 319.800 |
| 05/04/1999 | 12,19 | 12,94 | 12,19 | 12,53 | +2,82% | 6,15% | 178.600 |
| 01/04/1999 | 12,44 | 12,63 | 11,31 | 12,19 | -3,47% | 10,55% | 674.000 |
| 31/03/1999 | 12,56 | 12,81 | 12,44 | 12,63 | +1,51% | 2,99% | 184.200 |
| 30/03/1999 | 13,31 | 13,31 | 12,38 | 12,44 | -6,79% | 7,04% | 306.600 |
| 29/03/1999 | 12,50 | 13,38 | 12,44 | 13,34 | +8,38% | 7,50% | 389.400 |
| 26/03/1999 | 12,19 | 12,34 | 12,13 | 12,31 | +1,28% | 1,80% | 327.000 |
| 25/03/1999 | 12,00 | 12,22 | 11,81 | 12,16 | +2,37% | 3,39% | 384.200 |
| 24/03/1999 | 12,31 | 12,44 | 11,84 | 11,88 | -3,55% | 4,82% | 176.600 |
| 23/03/1999 | 12,75 | 12,81 | 12,31 | 12,31 | -4,37% | 3,92% | 250.200 |
| 22/03/1999 | 13,50 | 13,50 | 12,81 | 12,88 | -3,29% | 5,09% | 85.400 |
| 19/03/1999 | 13,16 | 13,50 | 13,13 | 13,31 | +0,95% | 2,85% | 475.600 |
| 18/03/1999 | 13,22 | 13,31 | 13,19 | 13,19 | -0,94% | 0,95% | 109.400 |
| 17/03/1999 | 13,81 | 13,88 | 13,13 | 13,31 | -4,27% | 5,43% | 124.600 |
| 16/03/1999 | 13,56 | 14,06 | 13,44 | 13,91 | +2,53% | 4,61% | 214.600 |
| 15/03/1999 | 13,44 | 13,63 | 13,00 | 13,56 | +1,40% | 4,65% | 158.200 |
| 12/03/1999 | 13,63 | 13,63 | 13,25 | 13,38 | -0,93% | 2,75% | 108.800 |
| 11/03/1999 | 13,50 | 13,63 | 12,75 | 13,50 | +2,61% | 6,48% | 292.800 |
| 10/03/1999 | 13,50 | 13,72 | 13,13 | 13,16 | -1,17% | 4,40% | 185.400 |
| 09/03/1999 | 13,56 | 13,69 | 13,31 | 13,31 | -0,47% | 2,76% | 195.800 |
| 08/03/1999 | 12,94 | 13,38 | 12,75 | 13,38 | +4,39% | 4,83% | 617.200 |